Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I really enjoy this message board because it helps us all learn. Most message boards that Ive seen do not do that. But I do enjoy this one.
Give me your thoughts on why you bought a ton of bmy. I don't know the future of immunology nor do I think anyone dose. But I love to here different thoughts.
As James Allison said. Theres two thousand clinical trials going on in immunology. That may be a little unnerving to investors but imo thats pretty cool to the patients and there families.
LOL, A giant pharma company (bmy) just got nervous and bought a car t tcr technology company. But thats not why they bought them. Imo. They are trying to diversify out of immunology because there scared they made the wrong bet, imo. Any other thoughts. PDL1 and the four or five immunology paths are in there infinsey. And there scared they made the wrong bet.
Yes, it seems this stock should be between 10 and 20 not 5 and 10. It must be all the progress thats being made in immunology thats holding it back. People are unsure about what the next break through will be and who will be the leader. Otherwise it seems this should easily be a 20 dollar stock. IMO.
Sorry I was more specific or able to post the link. Yes hanscott that is the video I was referring to. It sounds like they only targeted one neo antigen but had remarkable success with this lady.
Thats interesting too, but this lady had breast cancer and it didnt sound like a car t or tcr therapy.
Have you seen this one on youtube? Cutting-edge immunotherapy removes all cancer in woman. (Its a cbs news story) Sorry I could not get the link to post. It sounds very much what maker is doing, but I'm not sure would love to here other thoughts on if it is the same. Sounds like this was done in a lot higher dose than what marker uses. It did not sound like car-t or tcr to me though. Would love to here other opinions.
Thanks Hanscott
Form 10Q quarterly report. In the report marker talks about tpiv200 and the 80 patient trial in tnbc. They say key data from the trial is (a phase two trial) expected to be included in a future biologics application submission to the FDA for marketing clearance. Can any body help me understand what this might mean? Wouldn't marker have to complete a phase 3 trial to get marketing clearance? What kind of time frame are we looking at to get approval? Best and worst case?
Phantom Lord, Cincinnati Kid. What are your thoughts on the data between the active disease groups and adjuvant groups in the studys?
Maybe pollystart will turn out to be an important first step.
It seems to me but im know expert that all of mrkrs cell therapies work best when there is no longer active disease. This seemed to be true (at least as far as I can tell more so in mm). To me its showing that patients should be treated by some other form first or may need to be treated with some other form afterwords then perhaps followed up by another treatment from mrkr. I'm with you antimarv I'd love to here some more opinions. I may have that all wrong.
Thank you
Hi antimarv, I could not get the other link to work with my software, If youve got one that would be great. Also where is this presentation page?
Im curious if sevion/(later eloxx) anounced they were planning on launching a phase two trial in cancer but then didn't do it and curious if they let barry honig know this ahead of time?
How does the right to try law work? Has it ever been used or will it ever be used. Is it even practical? It seems the drug companies for liability reason aren't going to allow people to be using there drugs unless there approved.
I agree gotta get it. Anybody have any thoughts on fast track or right to try when it comes to tpiv200. It seems theres maybe enough data there that it could help a lot of people that have nothing else.
Tell them not to keep us in the dark intentionally for there own benifit.
Phantom, tell them to tell us about the compition and how they are doing in comparison to them. Tell them not to keep us in the dark. (They are experts and know)
I hope you send another agitated email.
Phantom, if you could pass along to the company that even the small guys expect to be fully informed right away like the big guys. That would be great. We were waiting on if there was synergy in the combo study like was talked about in starting a fire in tumors.
All sounds good except ive been burned before because of compition i didn't know about but the company did but failed to mention. Im hopeing we can all keep each other infored even if marker don't. Any thoughts?
Hi Unoq, I'm probably not the one to explain it ive only been here maybe 4 months. How long have you been following this stock? I showed up here because juno and kite put the hurt on one of my stocks. So ive been following cell therapy.
I think I was wrong on that. I thought I saw it on markers web sight. But just checked. I probably mistook it for a different trial.
Tpiv200 combo trial herceptain i believe is recruiting now. How long before we will probably get some kind of data on that trial? Could we see some data in 6 months?
There was more info released on a combo clinical trial by sellas today. In combo with herceptin. Im thinking what we have might be better since the DOD is funding the tpiv200 and herceptin. Any thoughts on there data or if the DOD may fund another study for them. I think the DOD funded there first trial.
Ann Leen is the only one i heard speak as to why they wanted to merge with tpiv. She spoke of tpiv's poly start. Any thoughts
All good info. That I did not know. Thank you
Hi Lady luck, I think your referring to the azn combo study. I hadn't heard that the trail wouldn't continue to the second half. Where did you see that?
Hopefully will get some good news when the interim data comes out.
If you figure it out you'll be a rich man
Ok, thanks
What book did everybody get? I didnt get a book.
Thanks everyone for the info
Phantom,I meet someone who has pancreatic cancer do you our dose anybody know what kind of success marker is having with solid tumors?
Anybody have info on how well markers phase 1 study did in breast and pancreatic . Efficacy wise. I see they're starting phase 2.
Thanks phantom. Im curious to see if the will say any more about the AZ combo study withe durvalumab. I think they gave a report a while ago saying there was a robust immune respose i think. But its hard to know if there was synergy. Is it possible or likely they want say anymore until the end of the study
Somebody posted the expected news and data release between now and the end of 2019. Dont remember who but perhaps they could repost it. That would be great.
It seems good the DOD,chose to fund markers combo study (with herceptin). After seeing the results of sellas and herceptin. Any inf or thoughts from anyone and sellas results